Objective: To determine the relationships between Krü ppel-like factors (KLF) 2 and 4, immune-activation, and subclinical vascular disease in HIV-infected patients on antiretroviral therapy (ART).
Introduction
There is increasing evidence that immune activation and inflammation contribute to cardiovascular disease (CVD) in the general population [1, 2] . Patients infected with HIV have an increased risk for CVD compared with HIV-uninfected controls despite effective antiretroviral therapy (ART), possibly because of residual immune Activated monocytes are critical to the initiation and progression of atherosclerotic CVD [14] . There exists three distinct subsets of monocytes based on CD14 and CD16 expression and each have distinct immunophenotypes [15] [16] [17] . Canonical monocytes, CD14 þ
CD16
À , are phagocytic and antigen presenting; patrolling monocytes, CD14 dim CD16
þ , express pathogen-recognition receptors and home to the endothelium; and proinflammatory monocytes, CD14
þ , produce inflammatory cytokines in response to antigen stimulation. HIV-infected patients without known coronary artery disease and HIV-uninfected patients that have had an acute coronary syndrome have similarly high levels of inflammatory and patrolling monocytes suggesting a shared proatherothrombotic phenotype [18] .
The role of T-cells in the progression of atherosclerosis is well described [1] . HIV infection causes heightened Tcell activation -often defined as coexpression of CD38 and/or human leukocyte antigen (HLA)-DR -that is only partially reversed by ART [19] and is an important predictor of mortality [20] . Further, cross-sectional correlations between T-cell activation and subclinical vascular disease have been described [8] [9] [10] , but the mechanisms linking T-cell activation and vascular disease in HIV-infected patients remain elusive.
Coronary artery calcification (CAC), as detected by ECG-gated noncontrast computed tomography (CT), is a marker of subclinical coronary atherosclerosis that predicts coronary events better than other surrogate measures of vascular risk [21] . Compared with HIVuninfected controls, HIV-infected patients on stable ART have a higher CAC burden [22, 23] . Similarly, highresolution ultrasound measures of carotid intima-media thickness (CIMT) also predict CVD risk in the general population, particularly stroke [24, 25] . Traditional and nontraditional risk factors are associated with elevated CAC and CIMT in patients with HIV [8, 9, 22, 23, [26] [27] [28] [29] . To date, transcriptional modulators that may explain these observations have not been identified.
The Krüppel-like factor (KLF) family of transcription factors has regulatory roles in cellular differentiation, metabolism, homeostasis, and cellular differentiation. Hemovascular expression of two members of the KLF family, KLF2 and KLF4, has been shown to modulate thrombosis, atherosclerosis, inflammation, barrier function, and vasomotor tone in cell and animal models of disease [30] [31] [32] [33] [34] [35] [36] [37] [38] . In addition, statins (HMG-CoA reductase inhibitors) significantly induce levels of KLF2 in mouse and human T cells [39] and KLF2 and KLF4 in human umbilical vein endothelial cell cultures [36] . The in-vivo effect of statins on KLF expression in humans is, however, as yet unknown. Given the important roles of KLF2 and KLF4 in modulating CVD progression and inflammation in cell and animal models of CVD, we hypothesized that KLF2 and KLF4 may play a role in mediating the inflammatory CVD phenotype in HIVinfected patients.
To address this question, we designed the current study to evaluate the associations between immune activation, subclinical vascular disease, and KLF2/4 expression in peripheral blood mononuclear cells (PBMCs) of a population of HIV-infected patients treated with ART. We further aimed to compare changes in KLF2/4 expression in PBMCs after 24 weeks of daily rosuvastatin vs. matching placebo.
Methods
Study population This is a substudy of the Stopping Atherosclerosis and Treating Unhealthy Bone with Rosuvastatin in HIV (SATURN-HIV) trial. SATURN-HIV is a randomized, double-blind, placebo-controlled trial aimed at elucidating the physiological effects of 10 mg/daily rosuvastatin on markers of subclinical cardiovascular disease, inflammation and skeletal health in patients with HIV on stable ART (clinicaltrials.gov identifier: NCT01218802). The institutional review board at University Hospitals Case Medical Center approved the study and written informed consent was obtained from each participant.
Participants in SATURN-HIV were HIV-infected adults at least 18 years of age, with HIV-1 RNA less than 1000 copies/ml, on stable ART for at least 3 months and cumulative ART for at least 6 months, fasting low-density lipoprotein cholesterol (LDL-C) of 130 mg/dl or less and fasting triglyceride level of 500 mg/dl or less. Additional inclusion criteria included evidence of heighted T Blood sample preparation PBMCs were separated from whole blood by centrifugation through a Ficoll-Hypaque gradient. All SATURN-HIV participants had PBMCs collected for T-cell and monocyte analysis. PBMCs not used for these analyses were stored for future studies. This KLF substudy was performed using only those participants (n ¼ 74) who had sufficient quantities of PBMCs available for further analyses at both baseline and at week 24.
Quantitative PCR RNA was isolated from PBMCs using Trizol (Life Technologies, Grand Island, New York, USA). Reverse transcription was then performed using a BioRad iScript kit (BioRad, Hercules, California, USA) and quantitative PCR (qPCR) was performed using the probe-based Lightcycler 480 system (Roche, Indianapolis, Indiana, USA). KLF2, KLF4, Hypoxanthine-guanine phosphoribosyltransferaseHPRT) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression levels were measured and the data herein represent an average copy number of KLF2 and KLF4 expression normalized to both housekeeping genes -HPRT and GAPDH. To determine absolute quantification of gene transcripts, we created a standard curve (copy number vs. Cp) using purified amplicon from each gene above, as described previously [41] . We subsequently derived copy number from a line of best fit for the standard curve using the Cp of each gene. The number of copies of KLF2/4 mRNA reported is that present in 20 pg of total cellular mRNA. Each patient's PBMC sample was run at least three times in triplicate.
Monocyte subsets
Whole blood was incubated for 15 min on ice in FACS lysis buffer (BD Biosciences) and washed in phosphatebuffered saline containing 1% bovine serum albumin and 0.1% sodium azide. The cells were then stained for 30 min in the dark on ice, washed and fixed in 1% paraformaldehyde. Monocyte subsets were defined by expression of CD14, CD16, size, and granularity [18] . In order to quantify expression of surface markers, we utilized isotype gating. The following fluorescent antibodies were used to identify monocytes: anti-CD14 (Pacific Blue, BD Pharmingen) and anti-CD16 (PE-conjugated, BD Pharmingen). Monocytes were analyzed for differential expression of CD14 and CD16 using a Miltenyi MACS quant flow cytometer and MACS Quantify software (Miltenyi, Auburn, California, USA). Monocyte subsets were defined using relative expression of CD14 and CD16.
T-cell activation T cells were quantified by size, granularity, and positive expression of CD3 þ and either CD4 þ or CD8
þ . T-cell activation was determined using PE-conjugated anti-CD38, FITC-conjugated anti-HLA-DR, peridininchlorophyll-protein-complex-conjugated anti-CD3, allophycocyanin-cy7-conjugated anti-CD8, and allophycocyanin-conjugated anti-CD4 antibodies all from BD Biosciences. T-cell activation was defined as expression of coexpression of CD38 and HLA-DR. Measurements were performed using a LSR II flow cytometer and analyzed using FACSDiva software (BD Biosciences, San Jose, California, USA).
Coronary artery calcium score Coronary artery calcium (CAC) score was performed as previously described [42] . Briefly, all patients underwent an ECG-gated noncontrast CT scan of the chest. Calcified lesions were quantified as areas of at least six pixels with density more than 130 Hounsfield units. The Agatston method was used to quantify CAC. Patients were categorized dichotomously as a score of 0 or more than 0.
Carotid intima-media thickness Vascular ultrasound to assess CIMT was performed as described previously [42] . CIMT was measured over the distal 1 cm segment of the common carotid artery at three angles bilaterally (i.e. six segments). Each of these six segments has a max value and a mean value over that 1 cm segment. Two measures were used for analysis: average of the six mean values (mean-mean IMT) and the average of the six max values (mean-max IMT).
Statistical analysis
Characteristics of study participants were described as median (interquartile range) for continuous variables and frequency (%) for categorical variables. Characteristics of those participants included in the KLF analysis were compared with the rest of the study population using an unpaired t-test or Wilcoxon Rank Sum test as distributionally appropriate for continuous variables and Fisher's exact test for categorical variables. Spearman's correlation was used to examine the relationships between KLF expression and markers of immune activation, subclinical vascular disease, and HIV-specific factors. Changes in KLF2/4 copy number from 0 to 24 weeks were expressed as percentage change from baseline and were compared between statin and placebo groups using paired t-tests. All statistical tests were two-sided and considered significant at a level of P < 0.05. Analyses were performed using SAS v. 9.2 (The SAS Institute, Carey, North Carolina, USA).
Results
Of 147 total participants in SATURN-HIV, 74 had sufficient quantities of PBMCs for inclusion in this KLF substudy. Baseline characteristics of the 74 study participants, including CVD risk factors and HIV disease status, are displayed in Table 1 . Median age was 47 and the majority were men. Participants had well controlled HIVinfection with high median CD4 þ T-cell count and 78% with undetectable HIV-1 RNA. Although median 10-year Framingham risk score was low (5% risk of cardiovascular disease), two-thirds were smokers and nearly one-quarter of participants had metabolic syndrome. Participants in the KLF analysis were similar to those who were not included (n ¼ 73), except that included participants were more likely to have undetectable (<48c/ml) HIV-1 RNA levels (78 vs. 63%, P ¼ 0.04, included vs. excluded; P > 0.05 for all other characteristics shown in Table 1 ). Total white blood cell count was higher among those who were included in the study compared with those who were not included (6.7 vs. 5.7 Â 10 9 cells/l); however, total lymphocytes and total monocytes were not different (both P > 0.2). All participants in this substudy completed a full 24 weeks of study therapy.
KLF4 positively correlates with monocyte and Tcell activation
We hypothesized that expression levels of KLF2/4 in PBMCs would be related to a study participant's level of immune activation at baseline. Copy number of KLF mRNA was determined using standard qPCR techniques. In a cross-sectional analysis of baseline data, KLF4 was positively correlated with two activated monocyte subsets: CD14 þ CD16 þ monocytes (r ¼ 0.34, P < 0.01) and CD14 dim CD16 þ monocytes (r ¼ 0.28, P ¼ 0.02) (Fig. 1a) . Similarly, we observed that KLF4 was positively correlated with activated CD8 (Fig. 1b) . Despite a borderline statistically significant positive correlation with total lymphocyte count (r ¼ 0.220, P ¼ 0.06) and a borderline negative correlation with total monocyte count (r ¼ À0.213, P ¼ 0.07), we observed no significant correlations between KLF2 and markers of activated monocytes or T cells (all P > 0.1).
KLF2 negatively correlates with coronary calcium score and carotid intima-media thickness Secondly, we hypothesized that KLF2 and KLF4 would also be related to measures of subclinical vascular disease. Indeed, KLF2 was negatively correlated with meanmean IMT (Table 2 ; r ¼ À0.231, P ¼ 0.048), mean-max IMT (r ¼ À0.271, P ¼ 0.020), and with the presence of coronary calcium (r ¼ À0.254, P ¼ 0.029). We found no significant correlation between KLF4 and CAC or IMT (Table 2 ; all P > 0.05).
KLF4 positively correlates with measures of HIV disease duration and antiretroviral therapy use
We further explored whether KLF2 and KLF4 would be related to measures of HIV disease severity and duration. KLF4 was negatively correlated with duration of HIV infection (r ¼ À0.297, P ¼ 0.01) and duration of ART (r ¼ À0.351, P ¼ 0.004), including protease inhibitor duration (r ¼ À0.322, P ¼ 0.02) and nucleoside reverse transcriptase inhibitor duration (r ¼ À0.307, P ¼ 0.009), but not nonnucleoside reverse transcriptase inhibitor duration (r ¼ 0.104, P ¼ 0.433). We did not observe any relationship between these measures and KLF2. Neither KLF2 nor KLF4 was associated with HIV-1 RNA level, current CD4 þ T-cell count, or nadir CD4 þ T-cell count (all P > 0.6).
Rosuvastatin therapy for 24 weeks does not alter the expression of KLF2 or KLF4 in peripheral blood mononuclear cells After 24 weeks of therapy, there were no significant changes in KLF2 or KLF4 expression in PBMCs of those treated with 10 mg of daily rosuvastatin compared with those who received placebo [mean (SD) change of þ0.4(1.8) vs. þ0.1(0.7)%, P ¼ 0.638 for KLF2 and þ2.7(6.2) vs. þ3.4(8.8)%, P ¼ 0.799 for KLF4, statin vs. placebo, respectively].
Discussion
Studies to elucidate the mechanisms that link immune activation and premature vascular disease in the HIV- Whereas the KLFs have diverse roles in fundamental physiological processes including cell differentiation and homeostatic balance, immune-cell expression of KLF2 and KLF4 in particular have been implicated in regulation of essential aspects of hemovascular biology [43, 44] . In animal models of disease, KLF2 and/or KLF4 expression in immune cells have been shown to protect from development of atherosclerosis [35] , insulin resistance, and obesity [37] , and regulate the immune response in inflammatory arthritis [45] , myocarditis [39] , and polymicrobial infection [46] . The precise transcriptional and signaling pathways by which KLF2/4 exert their immune effects is a subject of intense investigation. Several studies have shown roles for KLF2 or KLF4 in the regulation of T-cell and monocyte/macrophage activation in vitro and in vivo using cell culture and animal models [39, [47] [48] [49] [50] . Early in-vivo mouse studies suggested that the antiinflammatory transcription factor KLF2 maintains T cells in a quiescent state; however, subsequent studies indicate that KLF2 regulates a composite of T-cell functions, trafficking in particular, that can give the impression that it has a direct effect on quiescence [47, 48] . As reviewed by Hart et al. [43] , constitutive expression of KLF2 in naive T cells is extinguished after T-cell stimulation, and cytokines involved in effector differentiation repress re-expression of KLF2. Loss of KLF2 leads, in turn, to transcriptional downregulation of sphingosine 1-phosphate receptor 1, and thus activated T-cells are retained in lymphoid sites [51] . Furthermore, once CD8 þ T cells are activated, elevated levels of KLF2 are required to maintain the memory cell phenotype [52] . Of note, KLF2 also regulates expression of CCR5 in response to activation, thus making it a potential target to modify susceptibility to R5-tropic HIV-1 infection [53] . Susceptibility of CD4 þ T-cells to HIV-1 infection may be further increased by KLF2 regulated expression of CD62L (Lselectin) [54] . Finally, more recent data suggest that in addition to its important role in T-cell biology, KLF2 is also a negative regulator of monocyte activation [49] . Data regarding immune expression of KLF2 in humans are limited. Expression was shown to be decreased in circulating monocytes from patients with coronary artery disease [49] or by RNA analysis of whole blood in patients with sepsis [46] . In our study, we found no correlation between KLF2 copy number in PBMCs and levels of inflammatory monocyte subsets or CD38
þ HLA-DR þ T cells. Relationships between KLF2 and markers of T-cell turnover and senescence -which are altered by HIV infection -should be explored in future studies. The important role of the transcription factor KLF4 in monocyte and tissue macrophage activation has been previously described [50, 55] . Its role in T-cell activation is less clear, although it does appear to be required for Thelper 17 differentiation [56, 57] and is expressed in CD8 þ T cells wherein it contributes to T-cell quiescence downstream of Ets transcription factor ELF [58] . Inflammatory cytokines such as interferon and lipopolysaccharide induce tissue macrophages to produce KLF4 and overexpression of KLF4 induces macrophage activation [50] . As for KLF2, the expression in and role of KLF4 in immune tissue from human samples is limited. One study demonstrated a 50% reduction KLF4 expression in adipose tissue from obese (vs. lean) patients [36] . Decreased KLF4 signal was attributed to loss of expression in adipose tissue macrophages and hypothesized to play a role in the metabolic dysregulation seen in obese patients [36] . In this study, we report modest positive correlations between KLF4 copy number in PBMCs and activated CD8 þ CD38
þ HLA-DR þ T cells and proinflammatory CD14 þ CD16 þ monocytes. KLF4 was also positively correlated with CD14 dim CD16 þ monocytes, so-called 'patrolling monocytes.' These patrolling monocytes play a homeostatic role in maintaining a healthy endothelium, but can become activated in response to certain viral infections [16] . Higher levels of these monocytes have been associated with CAC progression [59] and carotid stiffness [60] in HIV-infected patients. Initiation of ART reduces T-cell activation [19] and starting ARTearlier in the course of HIV infection is associated with a lower T-cell activation setpoint [61] . The negative correlation between KLF4 levels and duration of ART in our study is, therefore, intriguing; however, whether KLF4 mediates the relationship between ART and immune activation requires further investigation in longitudinal clinical trials of ART.
Because our study population was extensively characterized by noninvasive vascular imaging tests, we were able to explore the relationship between KLF expression in PBMCs and the extent of subclinical atherosclerosis. We observed that HIV-infected patients with detectable coronary calcium and higher carotid IMT had lower levels of KLF2. It has long been recognized that KLF2 expression in endothelial cells is induced by shear stress [62] and that carotid IMT is thicker in areas of low shear stress such as the carotid bifurcation [63] ; however, to our knowledge, this inverse relationship between peripheral blood KLF2 expression and carotid IMT has not previously been described in humans. It is important to acknowledge that we did not directly measure endothelial KLF expression in this study. Despite correlations with cellular immune activation markers, KLF4 was not associated with any measure of subclinical atherosclerosis in our cross-sectional analysis.
Statins profoundly reduce the risk of cardiovascular events in multiple populations, and part of this risk reduction appears to be related to reductions in inflammation that are independent of LDL lowering [64, 65] . Prior studies have suggested that KLF2 and KLF4 may be important transcriptional regulators of this anti-inflammatory effect of statins [36, 39, 66, 67] . Surprisingly in the present study, there was no effect of 24 weeks of statin therapy on KLF2/ 4 levels in PBMCs. This is an important observation that must be confirmed in larger human studies. A potential explanation may be that the concentrations used in prior cell culture and small animal experiments (0.1-10 mmol) are much higher than the blood concentration of statins typically achieved in humans (0.001-0.015 mmol) [68] or that timing of blood draws and medication administration was mismatched to detect statin-mediated KLF expression. We measured KLF RNA expression in our study as a surrogate marker of protein levels in PBMCs. Many studies have shown strong correlation between RNA and protein [37, 38, 46, 55] ; however, there are no data on whether this relationship is altered by HIV infection. In this study, KLF RNA expression was measured in PBMCs. Future studies should assess the effect of statins on KLF expression in vascular endothelial cells. Finally, whether this lack of statin effect is unique to HIV-infected individuals is unknown and should be explored in HIVuninfected populations.
This study describes a novel examination of factors that transcriptionally regulate inflammation and vascular health in chronic HIV-infection. These transcription factors may also be altered by duration of ART use. The novel findings of this study are strengthened by the extensive immunophenotyping and subclinical vascular disease characterization of study patients. Limitations of this study include a relatively small sample size due in part to the time and expense required to measure KLF with qPCR; however it is larger than any previous study using human PBMCs. We cannot exclude the possibility that the observed relationships are explained by unmeasured confounding. Additionally, cross-sectional associations cannot determine causality.
In conclusion, KLF2 and KLF4 may play a role in mediating the inflammatory CVD phenotype in HIVinfected patients. Future studies should examine longitudinal relationships between KLF2/4, immune activation, and subclinical vascular disease. Regulation of KLF2/4 expression may represent a novel therapeutic target to prevent vascular disease in HIV infection and other chronic inflammatory diseases.
